ClinicalTrials.gg

Drug class

Calcium Channel Blockers clinical trials

A class of medicines: the studies that test any of its 52 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.

studies test it
1,918
open now
197
in phase 3
477
first study started
1992

Keep track of what changes. Save the calcium channel blockers studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

Medicines in this class

Studies that test each. A study of two counts under both, and once above.

Amlodipine, atorvastatin drug combination
4
Cinnarizine
2
Sor-c13
2

And 12 more, each tested in fewer studies.

Studies by the year they started

1,896 studies that test it; most in 2008 (101); 4 more planned to start later

Studies that test Calcium Channel Blockers, by start year
YearStudies
19921
19933
19943
19954
19977
199810
19998
200013
200120
200244
200341
200471
200571
200690
200795
2008101
200976
201081
201188
201283
201365
201487
201581
201668
201769
201870
201967
202070
202181
202274
202362
202467
202561
202664

By phase

A phase 1/2 study counts in both.

Early Phase 1
40
Phase 1
302
Phase 2
340
Phase 3
477
Phase 4
559
No phase
307

What it is tested for

Each study’s main condition, where its own words name it.

Who runs them

Industry 638 · Other 1,280

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (97) · Assiut University (49) · GlaxoSmithKline (47) · Novartis (37) · Cairo University (26) · Boehringer Ingelheim (23) · Pfizer (22) · Ain Shams University (20)

Studies

Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.

Testing one of them · 1,918

See all 1,918 studies that test one of the calcium channel blockers →

Codes

What other systems call Calcium Channel Blockers · ClinicalTrials.gg INT007118

  • MeSH (NLM) D002121Calcium Channel BlockersOne source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.